Its therapeutic potential is immense: glycerol phenylbutyrate (Ravicti) is currently used in a clinical trial in patients afflicted with SLC6A1‐ (i.e., GAT‐1) and syntaxin‐binding protein 1 (STXBP1)‐linked developmental and epileptic encephalopathy [65]. The gene discussed is STXBP1; the disease is developmental and epileptic encephalopathy.